What is the appropriate diagnostic and therapeutic approach for a 2‑year‑old male presenting with recurrent high‑grade fever, abdominal pain, tense ascites and hepatosplenomegaly on ultrasound, with a provisional diagnosis of hepatitis after initial ceftriaxone treatment?

Immediate Management: Discontinue Ceftriaxone and Perform Diagnostic Paracentesis

Stop ceftriaxone immediately and perform diagnostic paracentesis with ascitic fluid analysis (cell count with differential, protein, culture, and calculate SAAG) to differentiate between spontaneous bacterial peritonitis, ceftriaxone-induced hepatobiliary injury, and underlying liver disease.

Critical Diagnostic Considerations

This clinical scenario presents three urgent diagnostic possibilities that require immediate differentiation:

1. Ceftriaxone-Induced Hepatobiliary Complications

The FDA label explicitly warns that ceftriaxone causes gallbladder pseudolithiasis and pancreatitis secondary to biliary obstruction in pediatric patients 1. The drug can precipitate with calcium in the biliary system, appearing on ultrasound as sludge or stones. Additionally, ceftriaxone-induced cholestatic hepatitis, though rare, is well-documented in children and can present with hepatosplenomegaly and ascites 2, 3, 4. One case even reported fatal hepatitis with hemolysis leading to multiple organ failure 5.

Key point: The temporal relationship (fever recurrence after 3 days of ceftriaxone with new ascites) strongly suggests drug-induced injury rather than treatment failure.

2. Spontaneous Bacterial Peritonitis (SBP)

In children with ascites and fever, SBP occurs in 19-28% of cases 6. The diagnosis requires:

• Ascitic fluid PMN count >250/mm³ establishes SBP
• Gram-negative organisms predominate in pediatric SBP
• Blood cultures should be obtained simultaneously

3. Underlying Chronic Liver Disease

The SAAG (serum-ascites albumin gradient) differentiates portal hypertensive ascites (SAAG >1.1 g/dL) from other causes 7. However, acute ceftriaxone toxicity can mimic chronic liver disease presentation.

Immediate Diagnostic Algorithm

Step 1: Discontinue ceftriaxone - Given the high probability of drug-induced injury and FDA warnings about biliary complications in children 1

Step 2: Perform diagnostic paracentesis immediately 6:

• Cell count with differential (PMN count)
• Total protein and albumin (calculate SAAG)
• Gram stain and culture (aerobic and anaerobic)
• Simultaneous serum albumin measurement

Step 3: Obtain additional laboratory studies:

• Complete blood count (thrombocytopenia suggests portal hypertension or hemolysis)
• Comprehensive metabolic panel including liver enzymes (AST, ALT, alkaline phosphatase, bilirubin)
• Coagulation profile (PT/INR) - ceftriaxone affects vitamin K synthesis 1
• Viral hepatitis serologies (HAV IgM, HBsAg, HCV antibody)
• Blood cultures

Step 4: Repeat ultrasound with Doppler to assess:

• Biliary sludge or pseudolithiasis (ceftriaxone-induced)
• Portal vein patency and direction of flow
• Liver echotexture and surface nodularity

Therapeutic Management Based on Findings

If SBP is Confirmed (PMN >250/mm³):

Start broad-spectrum antibiotics covering gram-positive and gram-negative organisms 6. Do NOT restart ceftriaxone. Consider:

• Piperacillin-tazobactam 300 mg/kg/day divided every 6-8 hours, OR
• Meropenem 60 mg/kg/day divided every 8 hours

The guideline emphasizes that children require coverage for both gram-positive and gram-negative organisms, unlike adults where third-generation cephalosporins are standard 6.

If Ceftriaxone-Induced Injury is Suspected:

• Supportive care with close monitoring - liver enzymes typically normalize within 1 week of discontinuation 3, 8, 9
• Ensure adequate hydration per FDA recommendations 1
• Monitor coagulation parameters and administer vitamin K 10 mg if PT is prolonged 1
• Serial ultrasounds to document resolution of biliary sludge (usually reversible) 1

Management of Ascites:

For mild-moderate ascites in children 7:

• Sodium restriction (1-2 mEq/kg/day)
• Diuretics: Spironolactone 2-3 mg/kg/day plus furosemide 1-2 mg/kg/day
• Fluid restriction only if hyponatremic

For tense ascites:

• Large volume paracentesis with albumin infusion (1 g/kg for every 2-3 liters removed) 7

Critical Pitfalls to Avoid

1. Do not continue ceftriaxone - The FDA explicitly states to discontinue if signs of gallbladder disease, urolithiasis, or biliary obstruction develop 1

2. Do not assume treatment failure - Recurrent fever after initial improvement suggests drug toxicity or superinfection, not inadequate initial coverage

3. Do not delay paracentesis - This is the only way to definitively diagnose SBP, which has high mortality in children if untreated 6

4. Do not overlook coagulopathy - Ceftriaxone impairs vitamin K synthesis, especially in malnourished patients or those with liver disease 1

5. Do not restart ceftriaxone even if cultures are pending - Multiple alternative antibiotics are available, and documented cases show severe hepatotoxicity can be fatal in children 5

Monitoring and Follow-up

• Daily liver enzymes until downtrending
• Daily clinical assessment of ascites (abdominal girth measurement)
• Repeat ultrasound in 1-2 weeks to confirm resolution of biliary sludge
• Consider liver biopsy only if hepatitis persists beyond 2 weeks after ceftriaxone discontinuation, suggesting alternative diagnosis

The key to this case is recognizing that ceftriaxone itself may be causing the hepatosplenomegaly and ascites through biliary obstruction and hepatotoxicity, rather than representing treatment failure of an underlying infection 1, 2, 3, 4.